SS Innovations Announces Completion of World’s First Intercontinental Robotic Cardiac Telesurgery
SS Innovations (NASDAQ:SSII) has achieved a groundbreaking milestone by completing the world's first intercontinental robotic cardiac telesurgery. Dr. Sudhir Srivastava, the Company's CEO, successfully performed an atrial septal defect closure on July 19, 2025, operating remotely from IRCAD in Strasbourg, France, to control the SSi Mantra 3 surgical robot located over 4,000 miles away in Indore, India.
The procedure demonstrated flawless precision with imperceptible latency, showcasing the robustness of SSi Mantra 3's telesurgery capabilities. The system has already facilitated 35 telesurgeries, including 10 cardiac procedures, and a total of 5,000+ multi-specialty surgeries without device-related adverse events. SS Innovations is currently the only surgical robotic company with CDSCO approval for both teleproctoring and telesurgery in India.
SS Innovations (NASDAQ:SSII) ha raggiunto un traguardo rivoluzionario completando la prima telesurgia cardiaca robotica intercontinentale al mondo. Il dottor Sudhir Srivastava, CEO dell'azienda, ha eseguito con successo la chiusura di un difetto del setto atriale il 19 luglio 2025, operando da remoto presso IRCAD a Strasburgo, Francia, controllando il robot chirurgico SSi Mantra 3 situato a oltre 4.000 miglia di distanza a Indore, India.
La procedura ha dimostrato una precisione impeccabile con una latenza impercettibile, evidenziando l'affidabilità delle capacità di telesurgia del SSi Mantra 3. Il sistema ha già facilitato 35 telesurgie, di cui 10 procedure cardiache, e un totale di oltre 5.000 interventi multi-specialistici senza eventi avversi correlati al dispositivo. SS Innovations è attualmente l'unica azienda di robotica chirurgica con approvazione CDSCO per teleproctoring e telesurgia in India.
SS Innovations (NASDAQ:SSII) ha alcanzado un hito innovador al completar la primera telescirugía cardíaca robótica intercontinental del mundo. El Dr. Sudhir Srivastava, CEO de la compañía, realizó con éxito el cierre de un defecto del septo auricular el 19 de julio de 2025, operando de forma remota desde IRCAD en Estrasburgo, Francia, para controlar el robot quirúrgico SSi Mantra 3 ubicado a más de 4,000 millas de distancia en Indore, India.
El procedimiento demostró una precisión impecable con una latencia imperceptible, mostrando la solidez de las capacidades de telescirugía del SSi Mantra 3. El sistema ya ha facilitado 35 telescirugías, incluyendo 10 procedimientos cardíacos, y un total de más de 5,000 cirugías multispecializadas sin eventos adversos relacionados con el dispositivo. SS Innovations es actualmente la única empresa de robótica quirúrgica con aprobación CDSCO tanto para teleproctoría como para telescirugía en India.
SS Innovations (NASDAQ:SSII)는 세계 최초의 대륙 간 로봇 심장 원격 수술을 성공적으로 완수하며 획기적인 이정표를 세웠습니다. 회사의 CEO인 Dr. Sudhir Srivastava는 2025년 7월 19일 프랑스 스트라스부르의 IRCAD에서 원격으로 수술을 진행하여 인도 인도르에 위치한 4,000마일 이상 떨어진 SSi Mantra 3 수술 로봇을 조작하며 심방 중격 결손 폐쇄 수술을 성공적으로 수행했습니다.
이 수술은 미세한 지연 없이 완벽한 정밀도를 보여 SSi Mantra 3의 원격 수술 능력의 견고함을 입증했습니다. 이 시스템은 이미 35건의 원격 수술을 지원했으며, 그중 10건은 심장 수술이고, 총 5,000건 이상의 다학제 수술을 기기 관련 부작용 없이 수행했습니다. SS Innovations는 현재 인도에서 원격 지도 및 원격 수술에 대해 CDSCO 승인을 받은 유일한 수술용 로봇 회사입니다.
SS Innovations (NASDAQ:SSII) a franchi une étape révolutionnaire en réalisant la première téléchirurgie cardiaque robotisée intercontinentale au monde. Le Dr Sudhir Srivastava, PDG de l'entreprise, a réussi à fermer un défaut du septum atrial le 19 juillet 2025, opérant à distance depuis l'IRCAD à Strasbourg, France, pour contrôler le robot chirurgical SSi Mantra 3 situé à plus de 4 000 miles à Indore, en Inde.
La procédure a démontré une précision parfaite avec une latence imperceptible, mettant en avant la robustesse des capacités de téléchirurgie du SSi Mantra 3. Le système a déjà permis 35 téléchirurgies, dont 10 interventions cardiaques, et un total de plus de 5 000 interventions multispecialisées sans événements indésirables liés au dispositif. SS Innovations est actuellement la seule entreprise de robotique chirurgicale à détenir l'approbation CDSCO pour la téléproctoring et la téléchirurgie en Inde.
SS Innovations (NASDAQ:SSII) hat einen bahnbrechenden Meilenstein erreicht, indem das weltweit erste interkontinentale robotergestützte Herz-Telesurgery abgeschlossen wurde. Dr. Sudhir Srivastava, CEO des Unternehmens, führte am 19. Juli 2025 erfolgreich einen Verschluss eines Vorhofseptumdefekts durch, indem er aus der Ferne vom IRCAD in Straßburg, Frankreich aus den chirurgischen Roboter SSi Mantra 3 steuerte, der über 4.000 Meilen entfernt in Indore, Indien, stationiert ist.
Der Eingriff zeigte makellose Präzision mit kaum wahrnehmbarer Latenz und demonstrierte die Zuverlässigkeit der Telesurgery-Fähigkeiten des SSi Mantra 3. Das System hat bereits 35 Telesurgerien ermöglicht, darunter 10 Herzoperationen, und insgesamt über 5.000 multidisziplinäre Operationen ohne gerätebedingte Komplikationen durchgeführt. SS Innovations ist derzeit das einzige Unternehmen für chirurgische Robotik mit CDSCO-Zulassung für Teleproctoring und Telesurgery in Indien.
- Successfully completed world's first intercontinental robotic cardiac telesurgery with imperceptible latency
- Demonstrated proven track record with 5,000+ successful multi-specialty surgeries and zero device-related adverse events
- Only surgical robotic company with CDSCO regulatory approval for teleproctoring and telesurgery in India
- System has already facilitated 250 cardiac procedures and 35 telesurgeries
- None.
Insights
SS Innovations achieves groundbreaking intercontinental cardiac telesurgery, demonstrating revolutionary potential for global surgical access.
The successful completion of the world's first intercontinental robotic cardiac telesurgery represents a landmark achievement in medical technology. Dr. Srivastava performed an atrial septal defect closure from 4,000+ miles away with reportedly imperceptible latency - a critical factor for telesurgery viability. The technical challenges of maintaining precise control over such distances cannot be overstated.
What makes this particularly significant is the procedure type. Cardiac surgeries demand extraordinary precision and real-time responsiveness. The successful execution of an atrial septal defect closure - repairing a hole between heart chambers - validates that the SSi Mantra 3 system can handle complex soft-tissue procedures remotely. This isn't just incremental progress; it potentially reshapes the geographic boundaries of surgical expertise.
The company's regulatory approval from India's CDSCO for both teleproctoring and telesurgery provides important validation. With 35 telesurgeries (including 10 cardiac procedures) and 5,000+ multi-specialty surgeries completed using their system without reported device-related adverse events, the technology demonstrates meaningful clinical adoption and safety record.
This achievement addresses fundamental healthcare accessibility challenges. Regions lacking specialized surgical expertise could potentially receive care from distant experts, democratizing access to complex surgical interventions. For SS Innovations, this showcases their system's capabilities in perhaps the most demanding surgical application possible, positioning them uniquely in the surgical robotics market.
Performed by Dr. Sudhir Srivastava utilizing the Company’s SSi Mantra 3 surgical robotic system
Remotely conducted from IRCAD in Strasbourg, France, at an unprecedented distance of more than 4,000 miles to the operating room at SAIMS in Indore, India
FORT LAUDERDALE, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company’s Chairman of the Board and Chief Executive Officer, Dr. Sudhir Srivastava, M.D., successfully completed the world’s first intercontinental robotic cardiac telesurgery on July 19, 2025, utilizing the Company’s SSi Mantra 3 surgical robotic system.
Dr. Srivastava performed the cardiac procedure, a robotic atrial septal defect closure, remotely from the global headquarters of the Institute of Research Against Digestive Cancer (“IRCAD”) in Strasbourg, France, during the Society of Robotic Surgery (“SRS”) Annual Meeting at an unprecedented transmission distance of more than 4,000 miles to the operating room at the Sri Aurobindo Institute of Medical Sciences (“SAIMS”) in Indore, India.
Patient-side support in Indore was seamlessly coordinated by:
- Dr. Lalit Malik, Chief of Cardiac Surgery, Manipal Hospital, Jaipur;
- Dr. Ram Krishna Shukla, Cardiologist, SAIMS, Indore;
- Dr. Bipin Arya, Anesthesiologist, SAIMS, Indore; and
- the SS Innovations and SAIMS teams.
The live telesurgery was moderated by robotic cardiac surgeon Dr. Husam H. Balkhy, M.D., President of the International Society for Minimally Invasive Cardiothoracic Surgery (“ISMICS”) and Professor of Surgery and Director of Robotic and Minimally Invasive Cardiac Surgery at the University of Chicago Medicine.
Together, the team successfully completed the surgery without any technical issues and with an imperceptible latency, flawless precision, and seamless robotic control showcasing the robustness of the SSi Mantra 3 and its revolutionary telesurgery architecture.
Dr. Srivastava commented, “I would like to extend my gratitude to Dr. Vipul Patel, M.D., F.A.C.S., Chairman of the Society of Robotic Surgery for this opportunity at the SRS 2025 Conference, Dr. Mohit Bhandari, the IRCAD India team, and the entire SS Innovations team whose dedication and innovation made the world’s first intercontinental robotic cardiac telesurgery possible. This historic achievement not only demonstrates the advanced capabilities of our SSi Mantra 3 surgical robotic system but also further paves the way for redefining and democratizing global delivery of complex cardiac care, especially in regions with limited access to surgical expertise.”
The Company’s advanced SSi Mantra surgical robotic technology platform, including its cutting edge telesurgery capabilities, addresses traditional obstacles related to travel, time, cost, and surgical accessibility, creating a more efficient and equitable medical standard for both patients and surgeons.
To date, 35 telesurgeries including 10 cardiac procedures, and a total of 250 cardiac procedures have been successfully completed utilizing the SSi Mantra surgical robotic system. Cardiac-related procedures often rank among the most difficult operations to perform, which is testament to SSi Mantra’s capabilities in both telesurgery and complex soft-tissue surgeries in general. Additionally, over 5,000 multi-specialty surgeries have been successfully carried out with the SSi Mantra system without any device-related adverse events.
SS Innovations is the only surgical robotic company to have received a regulatory approval from the Central Drugs Standard Control Organization (“CDSCO”), which is India’s equivalent of the U.S. Food and Drug Administration, for both teleproctoring and telesurgery.
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com
Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com
FAQ
What milestone did SS Innovations (SSII) achieve in robotic surgery on July 19, 2025?
How many surgeries have been performed using the SSi Mantra surgical robotic system?
What regulatory approvals has SS Innovations (SSII) received for telesurgery?
Who performed the first intercontinental robotic cardiac telesurgery for SS Innovations?
What type of cardiac procedure was performed in the intercontinental telesurgery?
